| I-02 Chayan Acharya Population PK analysis of Pegaspargase in Japanese and non-Japanese patients with acute lymphoblastic leukemia Wednesday 10:00-11:30 |
| I-11 Marcus Baaz Model-based Prediction of Progression-Free Survival for Combination Therapies in Oncology Wednesday 10:00-11:30 |
| I-12 Annabelle Ballesta Quantitative Systems Pharmacology to Personalize Temozolomide-based Drug Combinations against Brain Tumors. Wednesday 10:00-11:30 |
| I-14 Imke Bartelink Physiologically based pharmacokinetic modelling of the PSMA radioligand 18F-DCFPyL to predict the tissue distribution in patients with prostate cancer Wednesday 10:00-11:30 |
| I-16 Maxime Beaulieu Simulation study to evaluate the identifiability of a non-linear multi-level joint model for the follow-up of patients with cancer Wednesday 10:00-11:30 |
| I-20 Elisa Borella Elacestrant Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Elacestrant Dose Recommendations in Metastatic Breast Cancer (mBC) patients Wednesday 10:00-11:30 |
| I-21 Muriel Boulton Exposure-Response (E-R) analysis of efficacy and safety of niraparib/abiraterone acetate combination in patients with metastatic castration-resistant prostate cancer Wednesday 10:00-11:30 |
| I-23 Aurore CARROT Prognostic value of the modeled CA-125 kinetics parameter KELIM-PARP in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study Wednesday 10:00-11:30 |
| I-24 Marc Cerou Semi mechanistic joint modeling of tumor dynamics and PFS in advanced breast cancer: leveraging data from early amcenestrant phase I-II trials Wednesday 10:00-11:30 |
| I-28 Siak-Leng CHOI Applying a quantitative system pharmacology (QSP) model to inform KRASG12C covalent inhibitors’ PK driver level needed for efficacy in patients with non-small cell lung cancer (NSCLC) Wednesday 10:00-11:30 |
| I-29 John Clements Model-Based Meta-Analysis in Newly Diagnosed and Relapsed Refractory Multiple Myeloma to Support Outcome-Efficacy Translations and Extrapolations Across Lines of Therapy Wednesday 10:00-11:30 |
| I-38 Xiaoqing Fan Pharmacokinetic and pharmacodynamic modeling of erythropoietin and romiplostim combination therapy in rats with chemotherapy-induced anemia and thrombocytopenia Wednesday 10:00-11:30 |
| I-40 Fernandez Teruel Carlos Exposure–response analysis of safety and efficacy of capivasertib administered as monotherapy or in combination with fulvestrant Wednesday 10:00-11:30 |
| I-44 Glenn Gauderat Mechanistic modelling of tumor uptake & interstitial receptor occupancy of PRS-344/S095012 using preclinical positron emission tomography data Wednesday 10:00-11:30 |
| I-46 Eva Germovsek A semi-mechanistic model to describe preclinical tumour viral dynamics of an oncolytic virus Wednesday 10:00-11:30 |
| I-48 Daniel Glazar A simulation-based sample size analysis of a joint model of longitudinal and survival data for patients with glioma Wednesday 10:00-11:30 |
| I-49 Xiaohua Gong Pharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements Wednesday 10:00-11:30 |
| I-50 Sebastiaan Goulooze Conditional overall survival (OS) simulations with a joint tumor size (TS)-OS model to support oncology development decision making Wednesday 10:00-11:30 |
| I-52 Jinju Guk Integration of early circulating tumour DNA (ctDNA) changes into tumour growth inhibition modelling. Wednesday 10:00-11:30 |
| I-56 Jennifer Hibma Population Pharmacokinetic Analysis of Elranatamab in Patients with Multiple Myeloma Wednesday 10:00-11:30 |
| I-59 Itziar Irurzun Arana Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer Wednesday 10:00-11:30 |
| I-67 Huub Jan Kleijn Population Pharmacokinetic Analysis of PD-L1 Checkpoint Inhibitor Cosibelimab in Subjects with Advanced Cancers Wednesday 10:00-11:30 |
| I-68 Fenja Klima Separating out multi-analyte endoxifen measurements: Derivation of a conversion factor to enable assessment of analytically heterogeneous clinical trial data Wednesday 10:00-11:30 |
| I-88 Elena Tosca Predicting tumor volume doubling time and progression-free survival curves in cancer patients from patient-derived-xenograft (PDX) models: a translational model-based population approach Wednesday 10:00-11:30 |
| I-89 Mira Tout A translational minimal physiologically-based pharmacokinetic (mPBPK) model to predict preclinical and clinical PK of MEN1703 in tissues Wednesday 10:00-11:30 |
| I-91 Lisa van der Heijden Quantification of the difference in oral docetaxel pharmacokinetics in patients with prostate cancer compared to patients with other solid tumours Wednesday 10:00-11:30 |
| I-95 Anyue Yin Population pharmacokinetics and toxicity analysis of high-dose methotrexate in patients with central nervous system lymphoma Wednesday 10:00-11:30 |
| I-96 Seok Kyue Yoon Disease progression modeling analysis of the change of bone mineral density by postoperative hormone therapies in postmenopausal patients with early breast cancer Wednesday 10:00-11:30 |
| III-10 Summer Feng Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin Thursday 10:15-11:45 |
| III-25 Marie Lambert Population pharmacokinetic model to assess bone marrow absorbed dose after 177Lu-Dotatate administration Thursday 10:15-11:45 |
| III-28 Félicien Le Louedec Model-informed precision dosing of high-dose IV busulfan in Thai pediatric patients Thursday 10:15-11:45 |
| III-29 Félicien Le Louedec Model-informed precision dosing of protein kinase inhibitors: benefits and limits. The example of imatinib. Thursday 10:15-11:45 |
| III-32 Apolline Lefevre A mechanistic PK/PD model to predict cytokine release and tumor cell killing associated to T-cell bispecific therapies Thursday 10:15-11:45 |
| III-39 Sarah Lobet Influence of body composition on the pharmacokinetics of monoclonal antibodies : example of cetuximab and bevacizumab Thursday 10:15-11:45 |
| III-41 Aurelie Lombard Exploring the use of constant and time-varying observation-based versus model-based tumour size metrics for early predictions of drug efficacy on overall survival in malignant pleural mesothelioma Thursday 10:15-11:45 |
| III-43 Vincent Madelain Impact of interaction model choice in PKPD analysis evaluating drug combination in TGI in vivo studies Thursday 10:15-11:45 |
| III-52 Mourad Mseddi Population pharmacokinetics of abiraterone in patients with metastatic castration resistant prostate cancer Thursday 10:15-11:45 |
| III-53 Ida Neldemo Application of tumor size modelling and simulations to support the dose selection of BI 907828 for a Phase II study Thursday 10:15-11:45 |
| III-58 Theodoros Papathanasiou Population pharmacokinetics of belantamab mafodotin in relapsed or refractory multiple myeloma patients with severe renal impairment Thursday 10:15-11:45 |
| III-60 Antoine Pitoy Contribution of modelling jointly progression-free survival and biomarker longitudinal data for therapeutic evaluation in oncology Thursday 10:15-11:45 |
| III-62 Alicja Puszkiel Nivolumab de-escalation in patients with complete response: model-based simulations of alternative dosing regimens and noninferiority clinical trials Thursday 10:15-11:45 |
| III-65 Pascale Rietveld Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin Thursday 10:15-11:45 |
| III-66 Maša Roganović Modelling fatigue events in prostate cancer patients on radiotherapy Thursday 10:15-11:45 |
| III-67 Davide Ronchi Model-based analysis of patient-derived organoids for evaluating anticancer drugs Thursday 10:15-11:45 |
| III-68 Alberto Russu Population pharmacokinetic modeling and bioequivalence clinical trial simulations of niraparib plus abiraterone acetate administered as single-agent combination and dual-acting tablets plus prednisone for the treatment of metastatic castration-resistant prostate cancer Thursday 10:15-11:45 |
| III-71 Javier Sanchez Fernandez Building evidence on the PKPD relationship with bispecific co-stimulatory antibodies using in vitro data: FAP-4-1BBL example Thursday 10:15-11:45 |
| III-72 Aymara Sancho Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: the interplay between cancer cells and components of the tumor microenvironment. Thursday 10:15-11:45 |
| III-75 Emilie Schindler Population PK-PD modeling and exposure-response analysis in multiple myeloma patients treated with intravenous forimtamig, a T-cell engaging 2:1 bispecific antibody targeting GPRC5D and CD3 Thursday 10:15-11:45 |
| III-76 Miriam Schirru A QSP model for predicting efficacy assessment of combined treatment of radiotherapy and anti-PD-1 for NSCLC patients through virtual clinical trials. Thursday 10:15-11:45 |
| III-77 Alejandro Serrano Alcaide Application of an immune-oncology framework to explore the role of regulatory T cells in antitumor response. Thursday 10:15-11:45 |
| III-79 Hinke Siebinga Optimizing radionuclide therapy with 177Lu-HA-DOTATATE in patients with neuroendocrine tumors using semi-physiological population PK models Thursday 10:15-11:45 |
| III-82 Tomás Sou Population PK/PD modelling of platelet dynamics for dose selection in patients with haematological malignancies Thursday 10:15-11:45 |
| III-84 Herbert Struemper Development of a joint tumor size (TS)–overall survival (OS) modelling and simulation (M&S) framework supporting oncology development decision making Thursday 10:15-11:45 |
| III-86 Zhiyuan Tan Population pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma Thursday 10:15-11:45 |
| III-87 David Ternant A multi drug disposition model accounting for rituximab antigen binding portion (Fab) and crystallizable (Fc) mediated drug disposition mechanisms Thursday 10:15-11:45 |
